Portfolio of Immune Checkpoint Inhibitor Stocks
Here are 4 companies that offer immune checkpoint inhibitor cancer treatments:
- AstraZeneca (AZN) - durvalumab Imfinzi
- Bristol-Myers Squibb (BMY) - nivolumab Opdivo and ipilimumab Yervoy
- Merck (MRK) - pembrolizumab Keytruda
- Roche Holding (RHHBY) - atezolizumab TECENTRIQ
|4 Checkpoint Inhibitor Stocks|
Stock Returns & Price Chart
Recent Prices &
|Roche Holding AG||RHHBY|
|Price data from Quandl as of most recent close.|
The 3 stocks included in the portfolio
computations are: AZN, BMY and MRK. The current value of the portfolio assumes that $3,333.33 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. RHHBY was excluded from the portfolio computations because of insufficient price data.
To inspect the performance of the Checkpoint Inhibitor Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.
The current value of a $10,000 investment is $35,740. The percent return is 257.40%. The annualized return is 13.58%.
|Return Summary for Checkpoint Inhibitor Stocks|
|Current Value of Investment||$35,740.27|
|Number Profitable Returns||6,875|
|Percent Profitable Returns||94.70%|
|Number Unprofitable Returns||385|
|Percent Unprofitable Returns||5.30%|
|Profitable to Unprofitable Returns Ratio||17.86|
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.